



# FROM BIOTECHNOLOGY & PHARMACEUTICAL RESEARCH TO COMMERCIAL PRODUCTS

8<sup>TH</sup> & 9<sup>TH</sup> SEPTEMBER 2009

## A DRHEA MASTER CLASS

DUBLIN REGION HIGHER EDUCATION ALLIANCE GRADUATE PROGRAMME

As part of the Dublin Region Higher Education Alliance Graduate Programme, the National Institute for Cellular Biotechnology in Dublin City University is hosting a master class for post-graduate students. Using specific examples this master-class will present the commercialisation process for a variety of biotechnology and pharmaceutical products and processes. The class will discuss FDA and other regulatory procedures involved in commercialisation of research. Also, it will outline the various career pathways involved. There will be ample time for formal and informal interaction with the expert speakers.

Those interested in attending should e-mail: [nicb.drhea@dcu.ie](mailto:nicb.drhea@dcu.ie). Please see application procedure

*“This initiative is part of the Dublin Region Higher Education Alliance (DRHEA) graduate strand funded by cycle II of the Strategic Innovation Fund”.*



## COURSE LEADERS

The course leaders for the Master-class will be **Dr. Kevin Scanlon** from UCLA, and **Dr. Alan Bunch** from the University of Bath.



**Dr. Kevin Scanlon** currently teaches courses on commercialisation of Pharmaceutical and Biotechnology products for the MBA at UCLA. He has had a varied career as a leading basic cancer researcher at City of Hope National Medical Centre in Duarte; as Vice-President for Cancer Research at Berlex Biosciences in San Francisco; as a Scientific Advisor to the Pasadena Angels VC group; as course director on Biotechnology commercialisation courses at Keck Postgraduate College in Pasadena and UCLA; and as CEO of a start-up company, Melanoma Inc.



**Dr. Alan Bunch** was Senior Lecturer in Microbial Biotechnology at the University of Kent, and is now at the University of Bath. He has extensive experience in University-industry collaboration with both large pharmaceutical companies such as Pfizer, and with smaller start of companies such as Powdereject, Oxyzyme and Viridian.

## APPLICATION PROCEDURE

APPLICATIONS BY **JULY 30TH** BY E-MAIL TO: [NICB.DRHEA@DCU.IE](mailto:NICB.DRHEA@DCU.IE)

Please complete the attached application form.

Priority will be given to Ph.D. students in the DRHEA partner colleges. Applications from other researchers will be considered if places remain available.

(Course limited to 40 to facilitate maximum interaction. Late applications will be considered only if places remain unfilled).

*"This initiative is part of the Dublin Region Higher Education Alliance (DRHEA) graduate strand funded by cycle II of the Strategic Innovation Fund".*